nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.11.2014 | Original Article

Metabolic parameters using ¹⁸F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma

verfasst von: Do-Hoon Kim, Bong-Il Song, Chae Moon Hong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to investigate predictability of occult lymph node metastasis (OLM) using metabolic parameters on pretreatment ¹⁸F-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/CT in squamous cell non-small cell lung carcinoma (SC-NSCLC) patients who were clinically node negative (cN0) before surgery.

Methods

A total of 63 cN0 SC-NSCLC patients (M/F = 61/2, mean age 64.1 ± 8.0) who underwent curative surgery with lymph node dissection were enrolled in this study. Metabolic tumor volume (MTV) of the primary tumor was obtained with a standardized uptake value (SUV) threshold of 2.5. Total lesion glycolysis (TLG) was calculated by multiplication of the MTV and its SUV_mean. Metabolic parameters (SUV_max, MTV, and TLG) and clinicopathological factors were analyzed for OLM.

Results

Of 63 patients, 12 (19.0 %) had OLM. Significantly higher SUV_max, MTV, TLG, and pathological tumor size were observed in patients with OLM. The optimal cutoff values for prediction of OLM determined using a receiver-operating characteristic (ROC) curve were 8.8 for SUV_max, 18.9 cm³ for MTV, 88.4 for TLG, and 2.8 cm for pathological tumor size. Univariate analysis showed correlation of SUV_max, MTV, and TLG with the rate of OLM. In multivariate analyses, high SUV_max and MTV showed an association with an increased risk of OLM, after adjusting for age, sex, pathological tumor size, T stage, and location.

Conclusion

Metabolic parameters on pretreatment ¹⁸F-FDG PET/CT were significant predictors for OLM in cN0 SC-NSCLC patients. Surgical planning can be tailored based on the parameters in order to reduce the risk of hidden residual lymph node metastases in patients.

Nur mit Berechtigung zugänglich

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11–30.PubMedCrossRef

Park HK, Jeon K, Koh WJ, Suh GY, Kim H, Kwon OJ, et al. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology 2010;15:1179–84.PubMedCrossRef

Li L, Ren S, Zhang Y, Guan Y, Zhao J, Liu J, et al. Risk factors for predicting the occult nodal metastasis in T1-2N0M0 NSCLC patients staged by PET/CT: potential value in the clinic. Lung Cancer 2013;81:213–7.PubMedCrossRef

Miyasaka Y, Suzuki K, Takamochi K, Matsunaga T, Oh S. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer. Eur J Cardiothorac Surg 2013;44:83–7.PubMedCrossRef

Rusch VW, Hawes D, Decker PA, Martin SE, Abati A, Landreneau RJ, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 2011;29:4313–9.PubMedCrossRefPubMedCentral

Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003;348:2500–7.PubMedCrossRef

Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011–9.PubMedCrossRef

Kim BT, Lee KS, Shim SS, Choi JY, Kwon OJ, Kim H, et al. Stage T1 non-small cell lung cancer: preoperative mediastinal nodal staging with integrated FDG PET/CT–a prospective study. Radiology 2006;241:501–9.PubMedCrossRef

Kim YK, Lee KS, Kim BT, Choi JY, Kim H, Kwon OJ, et al. Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients. Cancer 2007;109:1068–77.PubMedCrossRef

10.

Yoo SW, Kim J, Chong A, Kwon S-Y, Min J-J, Song H-C, et al. Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer. Nucl Med Mol Imaging 2012;46:286–93.PubMedCrossRefPubMedCentral

11.

Veeramachaneni NK, Battafarano RJ, Meyers BF, Zoole JB, Patterson GA. Risk factors for occult nodal metastasis in clinical T1N0 lung cancer: a negative impact on survival. Eur J Cardiothorac Surg 2008;33:466–9.PubMedCrossRef

12.

Gajra A, Newman N, Gamble GP, Kohman LJ, Graziano SL. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol 2003;21:1029–34.PubMedCrossRef

13.

Massard G, Ducrocq X, Kochetkova EA, Porhanov VA, Riquet M. Sampling or node dissection for intraoperative staging of lung cancer: a multicentric cross-sectional study. Eur J Cardiothorac Surg 2006;30:164–7.PubMedCrossRef

14.

Gonzalez D, de la Torre M, Paradela M, Fernandez R, Delgado M, Garcia J, et al. Video-assisted thoracic surgery lobectomy: 3-year initial experience with 200 cases. Eur J Cardiothorac Surg 2011;40:e21–8.PubMedCrossRef

15.

Tsutani Y, Miyata Y, Misumi K, Ikeda T, Mimura T, Hihara J, et al. Difference in prognostic significance of maximum standardized uptake value on [18F]-fluoro-2-deoxyglucose positron emission tomography between adenocarcinoma and squamous cell carcinoma of the lung. Jpn J Clin Oncol 2011;41:890–6.PubMedCrossRef

16.

Keyes Jr JW. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836–9.PubMed

17.

Vanderhoek M, Perlman SB, Jeraj R. Impact of the definition of peak standardized uptake value on quantification of treatment response. J Nucl Med 2012;53:4–11.PubMedCrossRefPubMedCentral

18.

Boellaard R, Krak NC, Hoekstra OS, Lammertsma AA. Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med 2004;45:1519–27.PubMed

19.

Kim DH, Son SH, Kim CY, Hong CM, Oh JR, Song BI, et al. Prediction for recurrence using F-18 FDG PET/CT in pathologic N0 lung adenocarcinoma after curative surgery. Ann Surg Oncol 2014;21:589–96.PubMedCrossRef

20.

Kim CY, Hong CM, Kim DH, Son SH, Jeong SY, Lee SW, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on (18)F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma. Eur J Nucl Med Mol Imaging 2013;40:1321–9.PubMedCrossRef

21.

Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, et al. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2014;41:50–8.PubMedCrossRef

Titel: Metabolic parameters using 18F-FDG PET/CT correlate with occult lymph node metastasis in squamous cell lung carcinoma
verfasst von: Do-Hoon Kim
Bong-Il Song
Chae Moon Hong
Shin Young Jeong
Sang-Woo Lee
Jaetae Lee
Byeong-Cheol Ahn
Publikationsdatum: 01.11.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 11/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2831-6

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2014

Do CSF levels of t-Tau, p-Tau and β1-42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease

Molecular imaging: the emerging role of optical imaging in nuclear medicine

Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients

89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer

Erratum to: Do CSF levels of t-Tau, p-Tau and β1–42 amyloid correlate with dopaminergic system impairment in patients with a clinical diagnosis of Parkinson disease? A 123I-FP-CIT study in the early stages of the disease

Ideas from the second UEMS conference on CME/CPD: new EU directives on a patients’ rights in cross-border healthcare and professional qualifications